Fasenra pen 30 MG/mlml
Ended Awarded Last action
- Contract number
- SPE2DR26FCPH4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,988
Award facts
- Contract value 100% obligated
- $4,987.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $4,987.50 to DMS Pharmaceutical Group Inc. for FASENRA PEN 30 MG/ML on January 15, 2026, with a completion date of January 16, 2026. This firm fixed-price delivery order was awarded without a set-aside designation to the woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. DMS Pharmaceutical Group, which has maintained a System for Award Management registration since 2001, serves as a critical supplier within the federal pharmaceutical supply chain, with particular focus on supporting Department of Defense medical facilities.
This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying IDC, designated SPE2DR and valued at $499,999,999, was awarded on November 13, 2025, and authorizes DLA to issue delivery orders for a comprehensive portfolio of pharmaceutical products including branded and generic prescription drugs, biologics, vaccines, and medical consumables to support military healthcare operations globally. The contract structure includes a 30-month base period with three 30-month option periods extending through December 31, 2036, positioning DMS Pharmaceutical Group as a regional prime vendor contractor supplying diverse pharmaceutical requirements across the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FCPH4?
SPE2DR26FCPH4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26FCPH4 worth?
The government has obligated $4,988 on SPE2DR26FCPH4.
Is contract SPE2DR26FCPH4 an order under another contract?
Yes. SPE2DR26FCPH4 is a delivery order under SPE2DR25D9131, an indefinite delivery contract.
Was contract SPE2DR26FCPH4 competed?
The extent of competition for SPE2DR26FCPH4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award